Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Eur Arch Psychiatry Clin Neurosci ; 274(4): 879-890, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38280948

ABSTRACT

More knowledge is needed about long-term ADHD medication and symptom, daily functioning, comorbidity, and tolerability outcomes. This "Long-term Medication for ADHD (LMA) trial" was a prospective observational 2-year trial in children and adolescents aged 6-18 years (extension of 1-year trial). Participants met criteria for DSM-5 ADHD (inattentive or combined), with complex comorbidities; autism spectrum disorder (31%), autistic traits (24%), oppositional symptoms (59%), anxiety (32%), dyslexia/language disorder (16%), borderline intellectual functioning (17%). Medication was individually tailored and followed-up at clinical visits (1, 2, 3, 6, 12, 18, 24 months). Primary outcome: Clinical Global Impression-Severity and Improvement scales (CGI-S, CGI-I). Secondary outcomes: Investigator-rated ADHD-Rating Scale, Weiss Functional Impairment Rating Scale-Parent report (WFIRS-P; Family, School Learning and Behavior, Life Skills, Self-Concept, Social Activities, and Risky Activities domains), comorbidity symptoms and adverse events (AEs). One hundred twenty-eight participants were enrolled (1-year trial only n = 27, LMA trial n = 101). Of these 29 (23%) discontinued, mainly due to AEs (n = 7), moving (n = 7), or no longer needing medication (n = 6). Main AEs were poor appetite, low mood, anxiety, irritability, fatigue. Improvements from baseline to 2 years were large in CGI-S (effect size (ES) 2.28), ADHD-RS (ES 2.06), and moderate to large in WFIRS-P (ES total 0.73, learning 0.4, family 0.67). Overall, the trial showed robust and sustained improvements in ADHD symptom severity and daily functioning over a period of 2 years of ADHD medication in children and adolescents with ADHD and complex comorbidities. Most AEs were mild. Comorbidity symptoms were improved after 1 year, particularly oppositional symptoms, depression, and anxiety.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Central Nervous System Stimulants , Comorbidity , Humans , Child , Attention Deficit Disorder with Hyperactivity/drug therapy , Adolescent , Male , Female , Central Nervous System Stimulants/administration & dosage , Central Nervous System Stimulants/adverse effects , Prospective Studies , Outcome Assessment, Health Care , Autism Spectrum Disorder/drug therapy , Autism Spectrum Disorder/physiopathology , Methylphenidate/administration & dosage , Methylphenidate/adverse effects , Methylphenidate/pharmacology
2.
Eur Arch Psychiatry Clin Neurosci ; 272(2): 291-299, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34420075

ABSTRACT

Documenting effectiveness of ADHD medication is essential throughout the course of treatment. A rating scale and a continuous performance test (CPT) with motion tracking were used to study the effect of ADHD medication including compliance during one year. Children (N = 78, age 6-18 years) with ADHD were tested with the QbTest at baseline, visit 1 (1 month after baseline) and visit 5 (12 months after baseline). The ADHD-Rating scale was rated by investigator interview at the same visits. QbTest results and ADHD-RS ratings showed reductions in symptoms on all cardinal parameters of the QbTest and on all ADHD-RS subscales between baseline and 1 month and between baseline and 12 months. There was a weak but significant correlation between the total change scores on the two measures from baseline to 1 month. Eighteen participants dropped out of the study before visit 5; at baseline, these children showed significantly lower results on the inattention parameter of the QbTest, with faster reaction time and lower variation in reaction time, suggesting they suffered less problems with inattention. Both the QbTest and the ADHD-RS showed robust ADHD symptom improvements indicative of medication effect, and the QbTest results might also predict non-compliance of medication. Further research is warranted to increase knowledge about reliable monitoring of long-term medication and compliance.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Central Nervous System Stimulants , Adolescent , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/psychology , Central Nervous System Stimulants/therapeutic use , Child , Humans , Neuropsychological Tests , Reaction Time/physiology , Treatment Outcome
3.
Proc Natl Acad Sci U S A ; 106(30): 12512-7, 2009 Jul 28.
Article in English | MEDLINE | ID: mdl-19597155

ABSTRACT

It generally is assumed that a common neural substrate mediates both the palatability and the reward value of nutritive events. However, recent evidence suggests this assumption may not be true. Whereas opioid circuitry in both the nucleus accumbens and ventral pallidum has been reported to mediate taste-reactivity responses to palatable events, the assignment of reward or inventive value to goal-directed actions has been found to involve the basolateral amygdala. Here we found that, in rats, the neural processes mediating palatability and incentive value are indeed dissociable. Naloxone infused into either the ventral pallidum or nucleus accumbens shell blocked the increase in sucrose palatability induced by an increase in food deprivation without affecting the performance of sucrose-related actions. Conversely, naloxone infused into the basolateral amygdala blocked food deprivation-induced changes in sucrose-related actions without affecting sucrose palatability. This double dissociation of opioid-mediated changes in palatability and incentive value suggests that the role of endogenous opioids in reward processing does not depend on a single neural circuit. Rather, changes in palatability and in the incentive value assigned to rewarding events seem to be mediated by distinct neural processes.


Subject(s)
Feeding Behavior/physiology , Food Preferences/physiology , Receptors, Opioid/physiology , Reward , Animals , Food Deprivation/physiology , Globus Pallidus/drug effects , Globus Pallidus/metabolism , Globus Pallidus/physiology , Male , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Neural Pathways/physiology , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Nucleus Accumbens/physiology , Rats , Rats, Long-Evans , Receptors, Opioid/metabolism
4.
Anim Behav ; 56(5): 1177-1183, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9819334

ABSTRACT

We studied how male fifteen-spined sticklebacks, Spinachia spinachia, vary in paternal competence, whether males advertise their competence and whether females prefer better fathers. In this species the male alone provides care for the offspring through nest building, fanning, cleaning and protecting the eggs. We found no female preference for larger males. Instead, females preferred males that during the subsequent paternal phase fanned their nests in shorter fanning bouts. Such males enjoyed a significantly higher hatching success because they fanned more often than males with longer fanning bouts. Males that fanned for short bouts during the paternal phase were also able to increase their fin beat rate. Frequent fanning and high fin beat rates may improve the flow of oxygen to the eggs. Beat rate may be a condition-dependent trait, because males that lost more weight were unable to increase their fin beat rate. During courtship, males perform behaviours such as displacement fanning and body shaking. Females preferred males showing more frequent body shakes during courtship. Body shake frequency correlated positively with hatching success, and negatively with mean fanning bout duration during the paternal phase. The results indicate that female S. spinachia show a preference for direct benefits in terms of better paternal care, and that males may signal this ability to females by shaking their body during courtship. Copyright 1998 The Association for the Study of Animal Behaviour.

5.
Phys Rev Lett ; 75(19): 3537-3540, 1995 Nov 06.
Article in English | MEDLINE | ID: mdl-10059611
6.
Phys Rev B Condens Matter ; 52(5): 3662-3675, 1995 Aug 01.
Article in English | MEDLINE | ID: mdl-9981494
7.
Phys Rev B Condens Matter ; 47(10): 5977-5983, 1993 Mar 01.
Article in English | MEDLINE | ID: mdl-10004545
8.
Phys Rev B Condens Matter ; 44(22): 12413-12416, 1991 Dec 01.
Article in English | MEDLINE | ID: mdl-9999397
9.
Phys Rev B Condens Matter ; 42(13): 8609-8610, 1990 Nov 01.
Article in English | MEDLINE | ID: mdl-9995039
11.
Phys Rev A Gen Phys ; 34(4): 3426-3434, 1986 Oct.
Article in English | MEDLINE | ID: mdl-9897661
12.
Phys Rev Lett ; 56(19): 2068-2071, 1986 May 12.
Article in English | MEDLINE | ID: mdl-10032849
13.
Phys Rev Lett ; 55(11): 1165-1168, 1985 Sep 09.
Article in English | MEDLINE | ID: mdl-10031745
17.
Swed Dent J ; 8(5): 251-5, 1984.
Article in English | MEDLINE | ID: mdl-6395418

ABSTRACT

It has been shown that stone models poured in impressions with silicone rubber tend to develop a surface with pits 0.1-1 mm in diameter, sometimes lying closely together over the whole die. Some investigators have considered these defects to be related to the high contact angle of elastomers. The present investigation has not been able to verify this statement but has instead called attention to the fact that silicone rubber, and particularly vinyl silicone: so-called A-silicone, when newly set, will generate a great deal of static electricity.


Subject(s)
Dental Impression Materials/pharmacology , Models, Dental , Silicone Elastomers/pharmacology , Dental Impression Technique , Electricity , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL
...